{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:44:52Z","timestamp":1793094292433,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2191,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1111\/j.1365-2133.2009.09214.x","type":"journal-article","created":{"date-parts":[[2009,4,11]],"date-time":"2009-04-11T03:44:18Z","timestamp":1239421458000},"page":"515-521","source":"Crossref","is-referenced-by-count":117,"title":["Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors"],"prefix":"10.1093","volume":"161","author":[{"given":"A.","family":"Osio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mateus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-C.","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Malka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Boige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrd1066","article-title":"Issues and progress with protein kinase inhibitors for cancer treatment","volume":"2","author":"Dancey","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1634\/theoncologist.12-7-840","article-title":"Erlotinib in non-small cell lung cancer treatment: current status and future development","volume":"12","author":"Gridelli","year":"2007","journal-title":"Oncologist"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB4","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB6","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","article-title":"Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study","volume":"23","author":"Burtness","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB7","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"van Cutsem","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2174\/187152009787047752","article-title":"Tyrosine kinase blockers: new hope for successful cancer therapy","volume":"9","author":"Pytel","year":"2009","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/107327480701400313","article-title":"EGFR targeting of solid tumors","volume":"14","author":"Rocha-Lima","year":"2007","journal-title":"Cancer Control"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB10","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB11","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2000.18.4.904","article-title":"Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin","volume":"18","author":"Baselga","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2008.01.001","article-title":"Chemotherapeutic agents and the skin: an update","volume":"58","author":"Heidary","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB14","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1634\/theoncologist.12-5-610","article-title":"Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management","volume":"12","author":"Lynch","year":"2007","journal-title":"Oncologist"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2006.04.062","article-title":"Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients","volume":"55","author":"Roe","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","article-title":"Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management","volume":"56","author":"Hu","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB18","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ejca.2006.11.016","article-title":"Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors","volume":"43","author":"Galimont-Collen","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB20","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB21","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB22","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB23","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-06-2610","article-title":"Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies","volume":"13","author":"Wacker","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB24","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1200\/JCO.2005.01.9570","article-title":"Abnormal hair growth in a patient with head and neck cancer treated with the anti-epidermal growth factor receptor monoclonal antibody cetuximab","volume":"23","author":"Montagut","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1463-1318.2008.01495.x","article-title":"Targeted therapy in colorectal carcinoma: more than a theory","volume":"10","author":"Pickering","year":"2008","journal-title":"Colorectal Dis"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB28","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/jnci\/dji104","article-title":"Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient","volume":"97","author":"Tonini","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB30","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1158\/1078-0432.CCR-04-0189","article-title":"Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer","volume":"10","author":"Park","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB31","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB32","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.2003.10.051","article-title":"Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"21","author":"Cohen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ctrv.2003.10.003","article-title":"Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation","volume":"30","author":"Thomas","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1053\/sonc.2002.35648","article-title":"Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody","volume":"29","author":"Needle","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(04)01467-6","article-title":"Monoclonal antibodies as therapeutic agents for cancer","volume":"5","author":"Harris","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/00015550310005898","article-title":"Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor","volume":"84","author":"Lee","year":"2004","journal-title":"Acta Derm Venereol (Stockh)"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB37","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB38","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1046\/j.1365-2133.2002.04864.x","article-title":"Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor","volume":"147","author":"van Doorn","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09214.x-BIB39","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2006.08.8005","article-title":"Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab","volume":"25","author":"Curran","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2009.09214.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2009.09214.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:45:23Z","timestamp":1676382323000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/161\/3\/515\/6642133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09214.x","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}